This randomized, blinded clinical trial involved 55 participants with obesity who were assigned to receive either tirzepatide or a placebo over an 18-week period, alongside a caloric restriction regimen. The study found that participants receiving tirzepatide experienced significantly greater weight loss compared to the placebo group
Research suggests complementary mechanisms provide broader pathway coverage
Diet and Zero Sugar are mostly branding differencesboth typically mean 0g sugar and 0g carbs per serving, just marketed to slightly different audiences
Most likely reality: microdoses produce small metabolic improvements - subtle visceral fat changes, modest improvements in insulin sensitivity, minor reductions in inflammatory signaling - that compound over time into meaningful clinical benefits
Data from a Phase 2a sub-study revealed a remarkable reduction in liver fat
The Phase 2 SYNERGY-NASH trial was a 52-week, dose-finding study that evaluated Tirzepatide in 190 participants with biopsy-confirmed MASH and moderate-to-severe (stage F2 or F3) liver fibrosis
